The role of L-DOPA in neurological and neurodegenerative complications: a review.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing mechanisms and applications of L-DOPA without systematic methodology
PubMed 40488810 · doi:10.1007/s11010-025-05324-w
What was done
This narrative review summarizes literature concerning the synthesis, pharmacokinetics, mechanism of action, and therapeutic utility of L-DOPA. It explores its established role in Parkinson's disease, potential applications across other neurodegenerative and neurological conditions (such as Alzheimer's disease, Huntington's disease, multiple sclerosis, Lewy body dementia, amyotrophic lateral sclerosis, epilepsy, and traumatic brain injury), and emerging drug delivery methods including nanotechnology.
What was found
The abstract reports no numerical metrics or statistical findings. It notes qualitatively that L-DOPA crosses the blood-brain barrier to restore dopaminergic neurotransmission, improving motor and cognitive function. It highlights that long-term therapy is hindered by motor fluctuations, dyskinesias, and diminishing efficacy, and notes that novel delivery systems (such as plant-derived carbon dots) and combination therapies are being investigated to mitigate these limitations.
Why it matters
This review provides an overview of dopamine precursor therapy beyond Parkinson's disease and outlines formulation strategies aimed at overcoming chronic dosing complications.
Limits
As a narrative review, the paper provides no primary empirical data or quantitative effect sizes in the abstract. It does not employ systematic search criteria, quality appraisal, or meta-analytic pooling.
Cited by
- supports Pure dopamine cannot cross the blood-brain barrier when ingested or administered peripherally, whereas L-DOPA does cross the blood-brain barrier.